Novo Nordisk shares fell 7 percent following the release of its long-term growth targets and pipeline sales goals. Telix Pharmaceuticals announced a $1.65 billion acquisition to bolster its radiopharmaceutical footprint, while Roche, Amgen, and Vertex posted positive clinical trial results across diabetes, Sjögren's disease, and kidney disease. Additionally, policy shifts impacted healthcare coverage as the US administration canceled hundreds of thousands of Obamacare enrollments.
01Earnings
Novo Nordisk Stock Falls 7% Despite $23 Billion Sales Target for Obesity Drugs
Novo Nordisk shares fell 7 percent on Monday after the Danish pharmaceutical company presented long-term financial ambitions at a markets day in London. The company aims to generate more than 150 billion Danish kroner, equivalent to $23 billion, in risk-adjusted pipeline sales by 2035. Management expects compound annual growth between 2026 and 2030 to match its industry peers while maintaining a broadly stable . Chief Executive Mike Doustdar acknowledged that semaglutide, the active ingredient in Wegovy and Ozempic, will lose patent exclusivity starting in the early next decade, including in the United States in 2032. The company plans to launch more than five medicines with blockbuster potential by 2030 and expand oral manufacturing capacity to reach over 60 million patients globally.
Telix Acquires ITM for $1.6 Billion to Expand Radiopharmaceutical Reach
Telix Pharmaceuticals is acquiring Isotope Technologies Munich for $1.65 billion upfront in a deal that expands its reach in radiopharmaceuticals. The transaction includes an additional $700 million in milestone payments tied to regulatory approvals and sales targets for ITM's lead candidate, ITM-11. Telix will also assume more than $300 million of ITM's at closing. ITM generated $273 million in in 2025, supported by strong growth in recent years. The combined company projects 2026 revenue to exceed $1.3 billion. ITM brings manufacturing infrastructure and a distribution network spanning more than 65 countries. The gives Telix control over supplies of radioisotopes including lutetium-177, actinium-225, and terbium-161. ITM-11 is a peptide receptor radionuclide therapy designed to treat gastroenteropancreatic neuroendocrine tumors. The U.S. Food and Drug Administration issued a complete response letter for ITM-11 last month, citing manufacturing issues at a third-party facility rather than clinical safety or data. ITM plans to resubmit its application following remediation talks. Post-acquisition, Telix shareholders will own approximately 76.3% of the combined company, with ITM backers holding the remaining 23.7%. The transaction has secured approval from Telix's board and investors representing more than 90% of ITM's shares, with closure expected by the end of 2026.
Boryung Signs $277 Million Anticancer Drug Supply Deal in China
Boryung signed a seven-year supply agreement worth $277.1 million with Yifan Pharmaceutical for the cancer drug Taxotere in China. The contract marks the largest supply deal in the Korean drugmaker's history and its first major commercial agreement since acquiring the global business of Taxotere from Sanofi. China represents the largest market by sales among the 19 countries and regions included in Boryung's of the drug. The agreement features annual minimum purchase commitments alongside compensation provisions for volumes falling below agreed targets, securing long-term visibility for Boryung's . Boryung will recognize revenue sequentially according to the product supply schedule. The company currently plans to supply Taxotere through existing manufacturing arrangements before gradually transferring production to its Yesan Campus in Korea, a transition requiring local technology transfers and regulatory approvals. Boryung previously executed a similar integration strategy after acquiring domestic rights to Eli Lilly's Gemzar and Alimta. Yifan Pharmaceutical, a drugmaker listed on the Shenzhen Stock Exchange, handles sales and marketing in China for Xeloda. Boryung has set a target of generating more than 300 billion won in global revenue by 2030 through stabilized Taxotere operations, manufacturing transfers, additional brand acquisitions, and the expansion of its contract development and manufacturing organization business.
Trump Administration Removes 750,000 Individuals From Obamacare Markets
The Centers for and Services canceled roughly 315,000 Affordable Care Act marketplace enrollments covering about 760,000 people last month, alleging widespread fraud. Vice President JD Vance announced the enforcement action during a Tuesday briefing alongside CMS Administrator Dr. Mehmet Oz. The White House Task Force to Eliminate Fraud led the cancellations and estimates the policy will save $2.2 billion in taxpayer-funded subsidies. An additional 419,000 people face verification checks to confirm legal U.S. residency and income eligibility. The administration also imposed a six-month suspension on new agents and brokers enrolling individuals in coverage. CMS Administrator Dr. Mehmet Oz claimed that roughly 35% of current Obamacare participants have never utilized the program for prescriptions or doctor visits. ACA marketplace enrollment grew from approximately 10 million people before the Covid-19 pandemic to roughly 22 million afterward following expanded subsidies under the 2021 American Rescue Plan. Those enhanced credits expired at the end of 2025, pushing premiums higher before this latest enforcement action.
Obamacare Enrollment (Millions)
Enrollment doubled from pre-Covid levels to 22 million after 2021.
Roche reported Phase 2 trial results for enicepatide showing a 2.65 percent reduction in HbA1c levels for diabetes patients receiving the 24-mg weekly dose over 48 weeks. The dual and GIP receptor agonist, acquired through the 2.7 billion dollar buyout of Carmot Therapeutics, also delivered a mean weight loss of 15.5 percent at the highest dose without a demonstrable plateau. Up to 90 percent of patients reached an HbA1c level of 6.5 percent or below in the trial. Gastrointestinal side effects caused 2 percent of treatment-group patients to discontinue, compared to 0 percent in the placebo cohort. Roche plans to start a glycemic-control program and cardiovascular outcomes trials in the first half of next year.
Enicepatide Phase 2 Trial Metrics (%)
HbA1c fell by 2.65 percent and weight dropped by 15.5 percent at week 48.
Amgen Announces Phase 3 Success for Sjögren's Disease Treatment
Amgen reported that its experimental drug dazodalibep met the primary objective in the first of two trials for Sjögren’s disease, driving the company's stock up as much as 5% on Tuesday. The OASIZ 301 study enrolled 651 patients with moderate-to-severe symptoms, showing statistically significant improvements on the EULAR Sjögren's Syndrome Disease Activity after 48 weeks compared to placebo. Dazodalibep, a fusion protein targeting the CD40-CD40L pathway, was acquired through Amgen's purchase of Horizon Therapeutics, which had originally obtained the via its 2021 buyout of Viela Bio. There are currently no -approved treatments capable of altering the course of the autoimmune condition, leaving patients reliant on symptom management. Investigators observed that side effects were generally mild to moderate, with common issues including nasal inflammation, urinary tract infections, hypertension, and infusion-related reactions. The company did not spot an imbalance in blood clots or opportunistic infections. A second Phase 3 study named OASIZ 303, focusing on patients with a high symptom burden, is expected to produce data in the fourth quarter. Regulatory approval will likely require positive readouts from both trials.
Vertex Prepares Broad Label Strategy for Kidney Disease Drug Ahead of Readout
Vertex Pharmaceuticals reported positive phase 2b data for its experimental kidney disease drug inaxaplin, positioning the company to pursue a broader label. The phase 2b Amplified trial enrolled 22 patients with APOL1-mediated kidney disease and modest proteinuria, alongside 17 patients with the disease and Type 2 diabetes. At Week 13, inaxaplin reduced urine albumin-to-creatinine ratio by 42.7% in the modest proteinuria cohort and by 17.3% in the Type 2 diabetes group. On a secondary endpoint measuring urine protein-to-creatinine ratio, the drug achieved declines of 44.7% and 25.4% across the respective arms. These populations are distinct from the pivotal phase 2/3 Amplitude trial, which recruited patients with severe proteinuria and no comorbidities. Vertex has completed enrollment in the Amplitude trial and expects to share data from a preplanned interim analysis early next year. Positive results from that analysis could support an application for accelerated approval. The Amplitude trial targets a population of approximately 150,000 patients in the U.S. and Europe, while an expanded label incorporating the Amplified cohorts would add roughly 100,000 more.
Amplified Trial UACR Reduction (%)
UACR fell 42.7% in modest proteinuria and 17.3% in Type 2 diabetes.
Strong clinical trial wins and aggressive sector acquisitions contrast sharply with major political headwinds and market disappointment over Novo Nordisk's long-term targets. Whether clinical expansion can offset rising regulatory interventions and corporate growth friction remains unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.